Teriflunomidu position in the treatment of multiple sclerosis

Abstract

Teriflunomide is registered for treatment multiple sclerosis in Czech Republic in stages of clinically isolated syndrome and relapsing-remitting MS. Teriflunomide has a new mechanism of action.

In inhibits the mitochondrial enzyme dihydroorotate dehydrogenase and leads to blockade of the pyrimidine synthesis. The efficacy of teriflunomide has been shown in clinicals trials.

Teriflunomide is quite well tolerated.

Keywords

• teriflunomid
• multiple sclerosis
• clinically isolated syndrome
• relapsed - reminentní form